Skip to main content

Table 2 The association of the gene expressions and pathological characteristics

From: A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer

Characteristic

No. of Patients

APTX mRNA

BRCA1 mRNA

ERCC1 mRNA

ISG15 mRNA

Topo1 mRNA

  

mean ± SD

mean ± SD

mean ± SD

mean ± SD

mean ± SD

Age, y

      

 ≥ 63

91 (52%)

4.81 ± 3.78

8.61 ± 5.73

15.28 ± 10.01

4.48 ± 3.69

8.03 ± 7.30

 < 63

84 (48%)

4.09 ± 3.76

7.90 ± 5.95

14.75 ± 9.28

5.79 ± 6.90

7.47 ± 5.81

Sex

      

 Male

131 (75%)

4.77 ± 3.33

8.41 ± 5.57

15.74 ± 10.19

5.54 ± 5.62

7.95 ± 7.17

 Female

44 (25%)

3.58 ± 3.29

7.92 ± 6.67

12.77 ± 7.30

3.53 ± 4.27*

7.21 ± 4.62

Tumor Site

      

 Distal stomach

62 (35%)

4.79 ± 2.87

8.97 ± 6.52

16.12 ± 10.36

7.05 ± 7.75

8.09 ± 5.93

 Proximal stomach

70 (40%)

4.16 ± 3.10

8.33 ± 5.72

13.97 ± 9.09

3.61 ± 2.64

7.40 ± 6.63

 Whole stomach

43 (25%)

4.60 ± 4.44

7.12 ± 4.74

15.31 ± 9.70

4.61 ± 3.43

7.06 ± 7.94

Stage

      

 I

20 (11%)

4.25 ± 4.47

5.91 ± 3.40

13.40 ± 7.07

1.89 ± 0.83

5.89 ± 4.03

 II

41 (23%)

4.19 ± 3.01

8.58 ± 5.09

14.70 ± 9.56

6.76 ± 7.96

8.91 ± 6.35

 III

110 (63%)

4.66 ± 3.38

8.19 ± 5.75

15.56 ± 10.16

4.67 ± 4.01

7.70 ± 7.07

 IV

4 (3%)

4.20 ± 4.61

15.88 ± 17.90

11.01 ± 5.00

7.25 ± 6.33

4.03 ± 1.63

Histological grade

      

 2

36 (21%)

5.05 ± 3.54*

10.97 ± 7.33

15.78 ± 9.52

4.86 ± 4.75

8.08 ± 6.61

 3

81 (46%)

3.92 ± 3.55

7.81 ± 5.16

14.30 ± 9.64

3.68 ± 2.75

7.18 ± 6.08

 Mixed 1–2

6 (3%)

3.63 ± 4.51

7.17 ± 2.13

15.17 ± 12.40

8.00 ± 8.94

8.42 ± 6.02

 Mixed 2–3

52 (30%)

4.55 ± 2.53

7.06 ± 5.27

15.65 ± 9.96

7.16 ± 7.74

8.44 ± 7.18

Lymph node metastasis

      

 No

40 (23%)

4.58 ± 3.39

8.70 ± 5.08

14.68 ± 7.31

5.97 ± 8.17

7.48 ± 4.47

 Yes

135 (77%)

4.46 ± 3.35

8.16 ± 6.05

15.16 ± 10.33

4.78 ± 4.12

7.87 ± 7.23

  1. * P < 0.05.